Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer, Novartis Seek Broad Orphan Drug Exemption From HCR Annual Fees

Executive Summary

Bayer and Novartis are among a number of companies pushing to ensure a broad interpretation of exemption for orphan drugs from the annual market-based fees that drug firms newly owe under the Affordable Care Act.

You may also be interested in...

IRS Annual Fee Rule For Brand Drug Manufacturers Clarifies Orphan Drug Exclusion, Part B Calculations

Policies outlined in the temporary rule will remain "applicable" until at least Aug. 15, 2014.

340B Orphan Drug Rule: Stakeholders Are Parsing ACA Statute – Should Some Indications Be Cheaper Than Others?

Health care institutions that benefit from the recent expansion of the 340B program are applauding the HHS Health Resources and Services Administration’s interpretation of an orphan drugs provision that allows more products to be available at a discount. But some others question whether it fits with the plain language of the statute.

Health Care Reform Costs To Biopharma In 2011

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts